

HEDIS® Tip Sheet

Osteoporosis Management in Women Who Had a Fracture (OMW)

Measure Description

The percentage of women 67-85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the 180 days (6 months) after the fracture.

Note: Fractures of finger, toe, face, and skull are not included in this measure.

Product Line: Medicare

☆ Medicare Star Measure Weight: 1

Measure Specification: Administrative Only

Intake Period: July 1st of the year prior to the measurement year to June 30th of the measurement year. The intake period is used to capture the first fracture.

**The intake period ends 6/30/25 but gaps can be closed through 12/31/2025 if it is within 180 days from the fracture*

2024						2025																	
Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun
MY 2025 Intake Period												MY 2026 Intake Period											

Codes Included in the Current HEDIS® Measure

Codes to Identify Bone Mineral Density Test and Osteoporosis Therapy

Description	Code
Fractures	ICD-10: M48.4xxx, M80.Xxxx, M84.3xxx, M97.Xxxx, S12.0xxx-S12.9xxx, S22.0xxx-S22.9xxx, S32.0xxx-S32.9xxx, S42.0xxx-S42.9xxx, S52.0xxx-S52.9xxx, S62.0xxx-S62.9xxx, S72.0xxx-S72.9xxx, S82.0xxx-S82.9xxx, S92.0xxx-S92.9xxx
Bone Mineral Density Tests	CPT: 76977, 77078, 77080, 77081, 77085, 77086 ICD-10: BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR00ZZ1, BR07ZZ1, BR09ZZ1, BROGZZ1
Osteoporosis Medication Therapy	HCPCS: J0897, J1740, J3110, J3111, J3489
Long-Acting Osteoporosis Medications (for inpatient stays only)	HCPCS: J0897, J1740, J3489

Medications

Osteoporosis Medications

Description	Prescription
Bisphosphonates	Alendronate, Alendronate-cholecalciferol, Ibandronate, Risedronate, Zoledronic acid
Other Agents	Abaloparatide, Denosumab, Raloxifene, Romosozumab, Teriparatide

Dementia Medications (Advanced Illness Required Exclusions)

Description	Prescription
Cholinesterase Inhibitors	Donepezil, Galantamine, Rivastigmine
Miscellaneous Central Nervous System Agents	Memantine
Dementia Combinations	Donepezil-memantine

Ways Providers can Improve HEDIS® Performance

- Utilize standing bone density testing orders for female patients within the appropriate age range.
- Keep in mind that patients who had a bone density test within 24 months prior to a fracture are excluded from the measure. Regular testing is recommended regardless of a recent fracture.
- Order a BMD test on all women with a diagnosis of a fracture OR prescribe medication to prevent osteoporosis (e.g., bisphosphonates) within 6 months of fracture date.
- Educate patients on safety and fall prevention.
- Recommend and help patients schedule osteoporosis screenings.
- Utilize telehealth visits to evaluate, document, and recommend medication, when appropriate.
- Ask female patients between 67 and 85 years of age if they have had any fracture since their last appointment.
- Providers can upload medical records that contain evidence of BMD in Availity HEDIS Portlet, Cozeva, fax, etc. to close a data gap if the patient has a screening on file.

Ways Health Plans can Improve HEDIS® Performance

- Educate members on safety and fall prevention.
- Recommend and help members schedule osteoporosis screenings.
- Pair DEXA scan with mammogram preventive screening; schedule both screenings at once to ensure compliance.
- Using the data to identify members with a recent fracture and ensure appropriate screening or treatment (BMD or medication to treat or prevent osteoporosis) has been considered.
- When engaging with female members between 67 and 85 years of age, ask if they have had a recent fracture. Schedule office visits promptly after the fracture event.
- Review and encourage osteoporosis medication adherence.

Required Exclusions

- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Members who die any time during the measurement year.
- Members who had a BMD test during the 730 days (24 months) prior to the episode date.
- Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to the episode date.
- Members who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days (12 months) prior to the episode date.
- Members who received palliative care any time during the intake period through the end of the measurement year.
- Members who had an encounter for palliative care (ICD-10-CM code Z51.5) any time during the intake period through the end of the measurement year. Do not include laboratory claims (POS: 81).
- Members 67 years of age and older as of December 31 of the measurement year who meet either of the following:
 - Enrolled in an Institutional SNP (I-SNP) any time during the intake period through the end of the measurement year.

- Living long-term in an institution any time during the intake period through the end of the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File.
- Members 67–80 years of age as of December 31 of the measurement year with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded:
 - Frailty. At least two indications of frailty with different dates of service during the intake period through the end of the measurement year. Do not include laboratory claims (POS: 81).
 - Advanced Illness. Either of the following during the measurement year or the year prior to the measurement year: (a) Advanced illness on at least two different dates of service. Do not include laboratory claims (POS: 81); (b) Dispensed dementia medication.
- Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty with different dates of service during the intake period through the end of the measurement year. Do not include laboratory claims (POS: 81).

All summaries of the measures contained herein are reproduced with permission from HEDIS® Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare, Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

COPYRIGHT NOTICE AND DISCLAIMER

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal non-commercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use (including but not limited to vendors using the measures and specifications with a product or service to calculate measure results), or any external reproduction, distribution and publication of the HEDIS measures or results (“rates”) therefrom must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA’s Measure Certification Program.

HEDIS measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided “as is” without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a HEDIS measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on HEDIS measures and specifications or data reflective of performance under such measures and specifications.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

CPT® codes, descriptions and other data are copyright 2024 American Medical Association (AMA). All rights reserved. CPT is a trademark of the AMA. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

Health Care Provider Taxonomy Code Set codes copyright 2024 AMA. The codes are published in cooperation with the National Uniform Claim Committee (NUCC) by the AMA. Applicable FARS/DFARS restrictions apply.

The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

The American Dental Association (ADA) holds a copyright to the Current Dental Terminology (CDT) codes contained in certain measure specifications. The CDT codes in the HEDIS specifications are included with the permission of the ADA. All uses of the CDT codes require a license from the ADA. No alteration, amendments, or modifications of the CDT or any portion thereof is allowed. Resale, transmission, or distribution of copies of the CDT or other portions of the CDT is also not allowed. To inquire about licensing, contact CDT-SNODENT@ada.org.

Some measure specifications contain coding from LOINC® (<https://loinc.org/>). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2024 Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and are available at no cost under the license at <https://loinc.org/kb/license/>.

“SNOMED” and “SNOMED CT” are registered trademarks of the International Health Terminology Standards Development Organisation (IHTSDO).

The CDC Race and Ethnicity code system was developed by the U.S. Centers for Disease Control and Prevention (CDC). NCQA’s use of the code system does not imply endorsement by the CDC of NCQA, or its products or services. The code system is otherwise available on the CDC website at no charge.

Certain NullFlavor codes are owned and copyrighted by Health Level Seven International (HL7®); 2024. “HL7” is a registered trademark of Health Level Seven International.

RadLex copyright 2014, The Radiological Society of North America (RSNA), all rights reserved. Licensed under RadLex License Version 2.0. You may obtain a copy of the license at: <http://www.rsna.org/radlexdownloads/> This work is distributed under the above noted license on an “AS IS” basis, WITHOUT WARRANTIES OF ANY KIND, either express or implied. Please see the license for complete terms and conditions.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the written permission of NCQA.

© 2024 by the National Committee for Quality Assurance
1100 13th Street NW, Third Floor,
Washington, DC 20005

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA. The NCQA HEDIS measure specification has been adjusted pursuant to NCQA’s *Rules for Allowable Adjustments of HEDIS*. The adjusted measure specification may be used only for internal quality improvement purposes.
Updated 1/30/2025.

